Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation
- 27 November 2008
- journal article
- research article
- Published by Wiley in Prenatal Diagnosis
- Vol. 28 (13) , 1209-1213
- https://doi.org/10.1002/pd.2149
Abstract
Objectives: To examine the effectiveness in screening for triploidy at 11 weeks to 13 weeks and 6 days of gestation by the combined use of the risk algorithms for trisomies 21, 18 and 13 based on maternal age, fetal nuchal translucency (NT) thickness, fetal heart rate (FHR) and maternal serum free β‐hCG and PAPP‐A.Methods: Prospective screening for trisomy 21, including 56 376 normal singleton pregnancies and 31 cases with triploidy (24 digynic and 7 diandric). Patient‐specific risks for trisomies 21, 18 and 13 were calculated by multiplying the age related risk for trisomies 21, 18 and 13 with the likelihood ratio (LR) for fetal NT and with a combined LR for FHR, free β‐hCG and PAPP‐A, respectively. Detection rates (DRs) and false positive rates (FPRs) for triploidy were calculated by taking the proportion with risks above a given risk threshold and standardized for maternal age according to the distribution of pregnancies in England and Wales in 2000 to 2002.Results: In digynic triploidy, free β‐hCG was 0.16 (range 0.02–0.95) MoM and PAPP‐A was 0.06 (range 0.02–0.47) MoM and the respective values for diandric triploidy were 8.74 (range 2.83–47.0) and 0.74 (range 0.32–1.51) MoM. Use of the trisomy 21 algorithm identified 5 of the 7 diandric cases and 3 of the 24 digynic ones at a 3% FPR. Combined use of the risk algorithms for trisomies 18 and 13 identified 20 of the 24 cases with the digynic triploidy at the FPR of 0.2%. When screen positivity was defined by a 3% FPR using the algorithm for trisomy 21 and an additional 0.2% FPR using the algorithms for trisomies 18 and 13, the total FPR was 3.1% and the DR was 84%.Conclusions: A beneficial side‐effect of first trimester combined screening for trisomies is the detection of a high proportion of fetuses with triploidy. Copyright © 2008 John Wiley & Sons, Ltd.Keywords
Funding Information
- Fetal Medicine Foundation (1037116)
This publication has 12 references indexed in Scilit:
- Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free -hCG and pregnancy-associated plasma protein-AHuman Reproduction, 2008
- First‐trimester screening for trisomy 21 by free beta‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A: impact of maternal and pregnancy characteristicsUltrasound in Obstetrics & Gynecology, 2008
- First- and Second-Trimester ScreeningObstetrics & Gynecology, 2007
- First-trimester screening for fetal triploidy at 11 to 14 weeks: a role for fetal biometryPrenatal Diagnosis, 2005
- Multicenter study of first‐trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk‐orientated two‐stage first‐trimester screeningUltrasound in Obstetrics & Gynecology, 2005
- UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestationThe Lancet, 1998
- Early prenatal diagnosis of triploidyAmerican Journal of Obstetrics and Gynecology, 1997
- Maternal Age and Gestational Age-Specific Risk for Chromosomal DefectsFetal Diagnosis and Therapy, 1995
- Parental origin of triploidy in human fetuses: evidence for genomic imprintingHuman Genetics, 1993
- The origin of human triploidsAnnals of Human Genetics, 1978